Absence of RKIP expression is an independent prognostic biomarker for gastric cancer patients

Carregando...
Imagem de Miniatura
Citações na Scopus
22
Tipo de produção
article
Data de publicação
2013
Título da Revista
ISSN da Revista
Título do Volume
Editora
SPANDIDOS PUBL LTD
Autores
MARTINHO, Olga
SIMOES, Kleber
LONGATTO-FILHO, Adhemar
JACOB, Carlos Eduardo
ZILBERSTEIN, Bruno
BRESCIANI, Claudio
GAMA-RODRIGUES, Joaquim
CECCONELLO, Ivan
ALVES, Venancio
REIS, Rui Manuel
Citação
ONCOLOGY REPORTS, v.29, n.2, p.690-696, 2013
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Gastric cancer is a leading cause of cancer-related mortality, and the presence of lymph node metastasis an important prognostic factor. Downregulation of RKIP has been associated with tumor progression and metastasis in several types of neoplasms, being currently categorized as a metastasis suppressor gene. Our aim was to determine the expression levels of RKIP in gastric tissues and to evaluate its impact in the clinical outcome of gastric carcinoma patients. RKIP expression levels were studied by immunohistochemistry in a series of gastric tissues. Overall, we analysed 222 non-neoplastic gastric tissues, 152 primary tumors and 42 lymph node metastasis samples. We observed that RKIP was highly expressed in similar to 83% of non-neoplastic tissues (including normal tissue and metaplasia), was lost in similar to 56% of primary tumors and in similar to 90% of lymph node metastasis samples. Loss of RKIP expression was significantly associated with several markers of poor clinical outcome, including the presence of lymph node metastasis. Furthermore, the absence of RKIP protein constitutes an independent prognostic marker for these patients. In conclusion, RKIP expression is significantly lost during gastric carcinoma progression being almost absent in lymph node metastasis samples. Of note, we showed that the absence of RKIP expression is associated with poor outcome features of gastric cancer patients, this being also an independent prognostic marker.
Palavras-chave
RKIP, gastric carcinomas, prognosis
Referências
  1. Akaishi J, 2006, ANTICANCER RES, V26, P4437
  2. Al-Mulla F, 2006, J CLIN ONCOL, V24, P5672, DOI 10.1200/JCO.2006.07.5499
  3. Al-Mulla F, 2008, J CLIN PATHOL, V61, P524, DOI 10.1136/jcp.2007.046987
  4. Baritaki S, 2009, ONCOGENE, V28, P3573, DOI 10.1038/onc.2009.214
  5. Baritaki S, 2009, CANCER RES, V69, P8376, DOI 10.1158/0008-5472.CAN-09-1069
  6. BERNIER I, 1984, BIOCHIM BIOPHYS ACTA, V790, P174, DOI 10.1016/0167-4838(84)90221-8
  7. Bonavida B, 2008, NITRIC OXIDE-BIOL CH, V19, P152, DOI 10.1016/j.niox.2008.04.018
  8. Chatterjee D, 2004, J BIOL CHEM, V279, P17515, DOI 10.1074/jbc.M313816200
  9. Chatterjee D, 2008, CLIN CANCER RES, V14, P2994, DOI 10.1158/1078-0432.CCR-07-4496
  10. Chen Y, 2008, J PROTEOME RES, V7, P5254, DOI 10.1021/pr800602c
  11. Crew KD, 2006, WORLD J GASTROENTERO, V12, P354
  12. Desai Anant M, 2004, Gastric Cancer, V7, P196, DOI 10.1007/s10120-004-0289-0
  13. Dicken BJ, 2005, ANN SURG, V241, P27, DOI 10.1097/01.sla.0000149300.28588.23
  14. Fenoglio-Preiser C, 2000, PATHOLOGY GENETICS T, P37
  15. Fu Z, 2006, PROSTATE, V66, P248, DOI 10.1002/pros.20319
  16. Fu Z, 2003, J NATL CANCER I, V95, P878
  17. GABBERT HE, 1995, CANCER, V76, P720, DOI 10.1002/1097-0142(19950901)76:5<720::AID-CNCR2820760503>3.0.CO;2-E
  18. Granovsky AE, 2008, CELL RES, V18, P452, DOI 10.1038/cr.2008.43
  19. Greene FL, 2002, AJCC CANC STAGING MA
  20. Hagan S, 2005, CLIN CANCER RES, V11, P7392, DOI 10.1158/1078-0432.CCR-05-0283
  21. HORI N, 1994, GENE, V140, P293
  22. Houben R, 2006, J INVEST DERMATOL, V126, P1135, DOI 10.1038/sj.jid.5700170
  23. Jazirehi AR, 2004, CANCER RES, V64, P7117, DOI 10.1158/0008-5472.CAN-03-3500
  24. Jia BQ, 2012, TUMOR BIOL, V33, P919, DOI 10.1007/s13277-012-0317-3
  25. Klysik J, 2008, CELL SIGNAL, V20, P1, DOI 10.1016/j.cellsig.2007.07.003
  26. Lauren T, 1962, ACTA PATHOL MIC SC, V64, P34
  27. Lee HC, 2006, GASTROENTEROLOGY, V131, P1208, DOI 10.1053/j.gastro.2006.07.012
  28. Li HZ, 2008, MOL CANCER RES, V6, P917, DOI 10.1158/1541-7786.MCR-08-0093
  29. Lorenz K, 2003, NATURE, V426, P574, DOI 10.1038/nature02158
  30. Martinho O, 2009, VIRCHOWS ARCH, V455, P277, DOI 10.1007/s00428-009-0821-z
  31. Martinho O, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030769
  32. Martinho O, 2012, J CLIN PATHOL, V65, P122, DOI 10.1136/jclinpath-2011-200358
  33. Milne AN, 2009, HUM GENET, V126, P615, DOI 10.1007/s00439-009-0722-x
  34. MING SC, 1977, CANCER, V39, P2475, DOI 10.1002/1097-0142(197706)39:6<2475::AID-CNCR2820390626>3.0.CO;2-L
  35. Minoo P, 2006, GUT, V55, DOI 10.1136/gut.2005.082859
  36. Minoo P, 2007, AM J CLIN PATHOL, V127, P820, DOI 10.1309/5D7MM22DAVGDT1R8
  37. Pinheiro C, 2009, EUR J CANCER, V45, P2418, DOI 10.1016/j.ejca.2009.06.018
  38. Schuierer MM, 2004, CANCER RES, V64, P5186, DOI 10.1158/0008-5472.CAN-03-3861
  39. Schuierer MM, 2006, ONCOL REP, V16, P451
  40. SEDDIQI N, 1994, J MOL EVOL, V39, P655, DOI 10.1007/BF00160411
  41. Utsunomiya T, 1998, CLIN CANCER RES, V4, P2605
  42. Vauhkonen M, 2006, BEST PRACT RES CL GA, V20, P651, DOI 10.1016/j.bpg.2006.03.016
  43. Wang J, 2010, MED ONCOL, V27, P219, DOI 10.1007/s12032-009-9194-z
  44. WASHINGTON K, 1994, HUM PATHOL, V25, P1043, DOI 10.1016/0046-8177(94)90063-9
  45. Yeung K, 2000, MOL CELL BIOL, V20, P3079, DOI 10.1128/MCB.20.9.3079-3085.2000
  46. Yeung K, 1999, NATURE, V401, P173
  47. Yeung KC, 2001, MOL CELL BIOL, V21, P7207, DOI 10.1128/MCB.21.21.7207-7217.2001
  48. YONEMURA Y, 1995, CANCER, V76, P941, DOI 10.1002/1097-0142(19950915)76:6<941::AID-CNCR2820760606>3.0.CO;2-I
  49. Zaravinos A, 2009, CELL CYCLE, V8, P1402, DOI 10.4161/cc.8.9.8308
  50. Zhang LZ, 2004, SURGERY, V136, P708, DOI 10.1016/j.surg.2003.12.013
  51. Zlobec I, 2008, CLIN CANCER RES, V14, P143, DOI 10.1158/1078-0432.CCR-07-1380